Biocept to Present at the LD Micro 500 Virtual Conference

Rhea-AI Summary

Biocept (Nasdaq: BIOC) announced that President and CEO Michael Nall will present at the LD Micro 500 Virtual Conference on September 2 at 10:40 a.m. Eastern time. The live presentation can be accessed here and will also be archived on the Investor Relations section of its website. Biocept specializes in liquid biopsy tests for various cancers, using proprietary technology to aid physicians in treatment and monitoring.

SAN DIEGO, Aug. 27, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the LD Micro 500 Virtual Conference on Wednesday, September 2, at 10:40 a.m. Eastern time (7:40 a.m. Pacific time).

The live presentation can be accessed here and will be archived on the Investor Relations section of the Biocept website.

About Biocept 
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. In addition, Biocept recently added COVID-19 testing to support efforts to fight the pandemic. For additional information, please visit www.biocept.com.

Investor Contact: 
LHA Investor Relations  
Jody Cain
Jcain@lhai.com  
310-691-7100

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-ld-micro-500-virtual-conference-301118746.html

SOURCE Biocept, Inc.

FAQ

When will Biocept present at the LD Micro 500 Virtual Conference?

Biocept will present at the LD Micro 500 Virtual Conference on September 2 at 10:40 a.m. Eastern time.

Who is presenting for Biocept at the conference?

Michael Nall, President and CEO of Biocept, will be presenting at the conference.

How can I access the Biocept conference presentation?

The presentation can be accessed live here.

What is Biocept's focus in the diagnostic field?

Biocept focuses on liquid biopsy tests for various cancers, providing clinically actionable information for treatment and monitoring.

What technology does Biocept use for its liquid biopsy tests?

Biocept uses its proprietary Target Selector™ technology to analyze tumor-associated molecular markers in circulating tumor cells and circulating tumor DNA.